Interacting Drugs |
Magnesium carbonate, calcium carbonate, and folic acid vs Bisphosphonate Derivatives |
Security Level |
|
Mechanism |
Bisphosphonate Derivatives: Antacids may decrease the serum concentration of Bisphosphonate Derivatives. |
Management |
Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Exceptions: Pamidronate; Zoledronic Acid. |
Magnesium carbonate, calcium carbonate, and folic acid vs Bisphosphonate Derivatives
Post Review about Magnesium carbonate, calcium carbonate, and folic acid vs Bisphosphonate Derivatives Click here to cancel reply.
Other Interactions of Magnesium carbonate, calcium carbonate, and folic acid
Other Interactions of Bisphosphonate Derivatives
Magnesium carbonate, calcium carbonate, and folic acid vs Bisphosphonate Derivatives
Interacting Drugs |
Magnesium carbonate, calcium carbonate, and folic acid vs Bisphosphonate Derivatives |
Security Level |
|
Mechanism |
Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives. |
Management |
Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Exceptions: Pamidronate; Zoledronic Acid. |
No comments yet.
Post Review about Magnesium carbonate, calcium carbonate, and folic acid vs Bisphosphonate Derivatives Click here to cancel reply.
Other Interactions of Magnesium carbonate, calcium carbonate, and folic acid
Other Interactions of Bisphosphonate Derivatives
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.